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Summary Twenty cervical carcinomas were examined for loss of heterozygosity (LOH) using 22 RFLP
markers, which mapped to regions of putative oncosuppressor gene loci, identified as candidates in other
common solid tumours. Allele losses were identified in six of the eight chromosomal arms examined, but at a
significantly lower frequency than that reported in other common solid tumours. No association was observed
between allele losses at any chromosomal location and the presence or integration of 'high risk' types of HPV
determined by a sensitive, specific PCR method. HPV 16, 18 or 33 were found in the majority (75%) of these
tumours. We have looked at only a limited subset of chromosomal regions, but the results, so far, imply that
carcinoma of the cervix may arise by different molecular events than other common solid tumours, and
support the view that one of the distinctive events may be infection with HPV. Alternatively, similar molecular
events may be occurring, but in regions of the genome not yet identified as targets in other solid tumours.
Fundamental changes contributing to carcinogenesis include
oncogene activation and tumour suppressor gene inactivation
or loss (Knudson, 1989). The location of candidate tumour
suppressor genes can be identified by restriction fragment
length polymorphism (RFLP) analysis.
A number of putAtive tumour suppressor genes have now
been identified (Ponder, 1988; Sager, 1989), and include the
prototype retinoblastoma tumour suppressor gene located at
13q.14; two possible Wilms' tumour genes sited at llp.13
and llp.15; the p53 gene at 17p.13; the neurofibromatosis
NF-1 gene on 17q; a gene or genes in the region 3p.21
commonly deleted in small cell lung carcinoma and renal
carcinoma; the DCC gene deleted in colorectal carcinoma in
the region 18q.21-qter; the MCC gene, mutated in colorectal
cancer, and the APC gene (responsible for familial
adenomatous polyposis coli) both found in the 5q.21 region.
The location of candidate tumour suppressor genes can be
identified by the technique of restriction fragment length
polymorphism (RFLP) analysis in which labelled polymor-
phic probes are used as markers to identify individuals
heterozygous for specific chromosomal loci. Alleles present in
tumour DNA from heterozygous individuals can then be
compared with those present in the corresponding constitu-
tional DNA to detect allele loss or loss of heterozygosity
(LOH). Such LOH in the vicinity of putative oncosuppressor
gene loci has been used as support for Knudson's 'two-hit'
hypothesis of carcinogenesis (Knudson, 1989) involving loss
of gene function by homozygous inactivation of tumour
suppressor genes. Using RFLP analysis, allele losses in the
vicinity of oncosuppressor gene loci have now been observed
in a high proportion of several common solid human
tumours. These losses have been observed in cancers of
breast (17p, 17q) (Mackay et al., 1988a; Sato et al., 1991),
colon (5q, 17p, 18q) (Vogelstein et al., 1988; Fearon et al.,
1990; Ashton-Rickardt et al., 1991; Purdie et al., 1991), ovary
(17p, 17q) (Eccles et al., 1990; Russell et al., 1990), lung (3p,
5q) (Naylor et al., 1987; Mori et al., 1989; Ashton-Rickardt
et al., 1991), kidney (3p) (Zbar et al., 1987), bladder (9q, 1 lp,
17p) (Tsai et al., 1990), brain (17p) (Fults et al., 1989), and
bone (13q, 17p) (Toguchida et al., 1988; 1989).
In cervical carcinoma, reports of cytogenetic data are few
and the numbers of tumours studied have been relatively
small. In general, the chromosomal picture has been extre-
mely variable and complex, with complete karyotyping
accomplished in only a few cases. Triploidy and tetraploidy
are not uncommon, but no single cytogenetic abnormality
has been consistently associated with this tumour type. As in
many other types of neoplasia, chromosome 1 has been
found to be involved in a non-random fashion, with aberra-
tions comprising both numerical changes and structural
rearrangements (Atkin & Baker, 1979; 1982; 1984). These
aberrations which include isochromosomes, deletions, dup-
lication, and associated translocations of both the long and
short arms, have also been associated with other chromo-
somes, including chromosomes 3, 4 or 5, 6, 11, 13, 17, 18 and
21 (Atkin & Baker, 1979; 1982; 1984). It has been suggested
that chromosome 17 derived markers, frequently present in
carcinoma of the cervix, may signify the importance of genes
on this chromosome. It has further been postulated that their
importance to the development of this cancer may lie in the
loss of recessive genes on chromosome 17p (Atkin & Baker,
1989). Furthermore, loss of heterozygosity in primary cer-
vical carcinomas has been reported on chromosomes 3
(Yokota et al., 1989), 11 (Riou et al., 1988; Srivatsan et al.,
1991), and 17 (Kaelbling et al., 1992).
In an attempt to learn whether known tumour suppressor
genes are involved in the genesis or progression of cervical
carcinoma, or whether the presence or integration of human
papilloma viruses (HPV) into host DNA influences the pat-
tern of molecular lesions, we examined 20 cases of cervical
carcinoma for loss of heterozygosity with 22 RFLP markers.
In so doing, we have looked at a limited subset of
chromosomal regions on 8 chromosomal arms namely 3p,
5q, 8q, lIp, 13q, 17p, 17q and 18q. With the exception of
that on 8q, the markers used all mapped to regions of
putative oncosuppressor gene loci, identified in other com-
mon solid tumours. The HPV status of each tumour was
examined, and an attempt made to relate the presence or
integration of HPV to the allele losses observed.
Materials and methods
Twenty paired tumour/blood samples were obtained from
consenting patients undergoing Wertheim's hysterectomy or
examination under anaesthesia prior to radiotherapy for
histologically confirmed and clinically overt cervical car-
cinomas. The blood samples were used for preparation of
constitutional DNA which was used as a matched control for
each corresponding tumour.
Three major cervical carcinoma types - squamous carcin-
oma, adenocarcinoma and adenosquamous carcinoma - of
various grades and stages were represented (Table II), and
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patients' ages ranged from 23-70 years.
Tumour tissue was snap frozen in liquid nitrogen
immediately after surgical removal, and stored at - 70°C
until DNA extraction. The presence of tumour tissue was
confirmed by microscopy. Macroscopic non-cancerous tissue
was trimmed from the specimen before DNA extraction, and
specimens with less than 70% carcinoma on frozen section
were discarded.
Ten jLg samples of high molecular weight DNA, extracted
from peripheral blood lymphocytes and homogenised fresh
tumour tissue, were digested with appropriate restriction
endonucleases (Table I), size fractionated by electrophoresis
on 0.8% agarose gels, and transferred to Hybond N nylon
membranes by Southern blotting.
Polymorphic DNA probes (Table I) were used to compare
tumour and constitutional genotypes. Probes were radio-
labelled with 32P-dCTP by a standard random multiprime
method (Amersham). Prehybridisation and hybridisation
were performed for 2 and 16 h respectively at 65°C using the
same buffer (2.5 x Denhardts, 0.1% SDS, 0.1% NaPPi,
5 x SSC, 0.01% denatured salmon sperm DNA). Filters were
washed at 65°C (4 x 15 min/0.1 x SSC, 0.1% SDS), auto-
radiographed at - 70°C (Kodak XAR-5 film/Dupont Light-
ning-Plus Intensifying screens), and the autoradiographs
interpreted after 1-14 days.
Primers specific for regions of the E6 gene of HPV types 6,
11, 16, 18 and 33, (Arends et al., 1991) were used in
polymerase chain reactions (PCR), with 500ng samples of
tumour DNA as template using 0.51fl Taq polymerase
(Northumbria Biologicals Ltd.) in a volume of 100 l per
reaction. Thirty-two to 35 cycles of annealing (50/55°C)
(2 min), extension (/20C) (3 min) and denaturation (94°C)
(1 min) were preceded by an initial 1.5 min denaturation step
and ended with a 10 min extension. The annealing tempera-
ture was optimised for, and therefore varied with each HPV
type (HPV 6 and 16 - 55°C; HPV 11, 18 and 33 - 50°C).
PCR products were size fractionated by electrophoresis on
3% agarose gels containing ethidium bromide, and the
Table I Frequency of LOH with 22 RFLP markers in 20 cervical
carcinomas
CHR. Locus Probe (enzyme) A/B Case Nos.
3p 3pter-p21 pEFD 145 (Rsa I) 1/4 6
5q 5q21 pL 5.62 (Bgl II) 1/2 14
5q 5q21-22 MC 5.61 (Msp I) 0/8 -
5q 5q-21 pEF 5.44 (Msp I) 2/11 13 & 16
5q 5q21-22 YN 5.48 (Msp I) 3/13 4, 5 & 16
5q 5q21 MN 2.3 (Msp I) 0/2 -
5q 5ql5-21 ECB 27 (Bgl II) 0/6
Any 5q 5/16
8q 8q22-23 TL 11 (Hind III) 1/7 13
1lp lIpl5.5 pEJ6.6 (BamH I) 1/15 13
lip Ilpter-llp15.4 PTH (PstI) 1/14 1
lip lIpl5.4 Calcitonin (Taq I) 3/10 4, 5 & 16
lip lIpl3 FSH P (Hind III) 0/4
Any lip 5/19
13q 13q14 ap68RS 2.0 (Rsa I) 0/14 -
17p 17pl13.3 aYNZ 22.1 (Taq 1) 1/12 13
17p 17pl3.3 aYNH 37.3 (Taq 1) 1/14 13
17p 17pl1.2-cen pEW 301 (Taq 1) 1/10 16
17p 17pl2-13 pBHP 53 (BamH I) 1/9 14
17p 17pl3 pMCT 35.1 (Msp I) 1/11 16
17p 17p13 C3068 (Hae III) 0/15
Any 17p 3/20
17q 17q23-25.3 apTHH 59 (Taq 1) 0/13
18q 18q21.3 pBV 15.65 (Msp I) 1/5 16
18q 18q21 SAM 1.1 (EcoR I) 3/12 7, 8 & 16
Any 18q 3/12
A = No. ofcasesshowingLOH; B = No. ofinformative cases. aProbe
detecting VNTR (Variable No. of Tandem Repeats) sequence.
presence of the relevant HPV sequences detected by ultra-
violet transillumination. A 1 kb lambda marker was electro-
phoresed concurrently for band size comparison.
Linearised HPV plasmid DNA was radiolabelled and used
as a probe in hybridisation experiments with Southern blots
of DNA from HPV-positive tumours. Band sizes on the
resultant autoradiographs were compared with that of the
linearised plasmid HPV DNA, and indicated whether the
viral DNA present in the tumour was episomal or integrated.
Results
The results of 211 RFLP analyses of constitutional and
tumour DNA samples from 20 patients with cervical car-
cinoma at 22 polymorphic loci are given in Table I. For each
of the 22 marker loci on eight autosomal chromosomal arms,
at least two and up to 15 cases were informative. In general,
a low overall incidence of LOH was reflected at each
oncosuppressor site tested.
Fifteen of the 22 markers revealed LOH in one or more of
the informative cases. The frequency of LOH amongst infor-
mative cases (Table I) ranged from 7% (pEJ6.6 and PTH) to
30% (Calcitonin). An incidence of 50% LOH occurred with
only one probe, pL5.62, in which one of only two infor-
mative cases showed LOH. However, over the whole series,
of 211 informative loci, only 22 sites (10%), distributed
amongst nine tumours, showed LOH.
The majority (11) of the 20 tumours showed no losses at
any tested site, and 12 of the examples of LOH were found
in just two of the 20 tumours. Clinically and histologically,
these two tumours (both squamous carcinomas) did not
appear to differ from the others.
Addressing specific chromosomal sites in turn, the com-
bined result with six RFLP markers on chromosome 17p
detected LOH at one or more loci in only three of 20
informative cases. All the LOH observed was compatible
with deletion involving the p53 gene in the vicinity of 17p.13.
No losses were observed amongst 13 informative cases on
17q using the VNTR probe THH59.
No losses were identified amongst 14 informative cases at
the locus defined by p68RS2.0 within the Rb gene on
chromosome 13q. On chromosome llp, the calcitonin locus,
the c-Ha-ras-1 locus defined by marker pEJ, and those
defined by markers PTH and FSH P were analysed. Five
losses occurred amongst 19 informative cases. Three cases
exhibited LOH at the calcitonin locus; one loss was observed
at loci defined by each of the markers pEJ and PTH; and no
losses were seen in four cases informative with FSH P.
The combined result of six RFLP markers pL5.62, MC
5.61, pEF 5.44, YN 5.48, MN2.3 and ECB 27 in the 5q.21
region on chromosome 5 revealed LOH in five of 16 infor-
mative cases. Losses were detected with pL5.62, pEF5.44,
and YN 5.48, while none was observed with MC 5.61, MN
2.3 or ECB 27.
We observed only one LOH amongst four informative
cases using the probe pEFD145 which recognises a sequence
within the chromosome 3p.21 band.
Two markers were used to detect losses on the long arm of
chromosome 18 - pBV15.65 and SAM 1.1. Of 12 informative
cases, three showed losses - two cases at the SAM 1.1 locus
and the other at both loci.
Lastly, one loss was observed in seven informative cases
(14%) at the locus defined by marker TL1I on chromosome
8q - so far not implicated as an oncosuppressor site, and
hence useful as a 'control' site.
Table II lists the chromosomal arms showing allelic dele-
tion(s) in each tumour, and shows the HPV type(s) that were
detected in association with each tumour by PCR analysis.
As expected, human papilloma virus was present in three-
quarters (15/20), and was integrated rather than episomal in
the majority (9/12). Neither viral presence nor its integration
correlated with LOH at any specific chromosomal region,
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and HPV types in 20 cervical carcinomas
studied
Case Histological FIGO Location of HPV type
No. type stage allele losses present
1 A lib 1lp -
2 S lb 16
3 AS lb 18
4 A lb 5q, llp 16& 18
5 S IlIb 5q, lip 16
6 S lb 3p -
7 S lb 18q 16
8 S lb 18q 33
9 S Illa
10 A lb - 18
11 S IVa - 16
12 S Ilb - 16
13 S Ilb 5q, 8q, lIp, 17p 16 & 18
14 S lb 5q, 17p -
15 S lb -
16 S lb 5q, lIp, 17p, 18q 16
17 S lb - 16
18 S Ilb - 18
19 S Ilb - 16
20 S ITlb - 16
S = Squamous; AS = Adenosquamous; A = Adenocarcinoma.
Discussion
The unimpressive incidence of LOH at the known onco-
suppressor sites in this series of cervical carcinomas contrasts
with that reported in other major solid tumours (Table III).
Although only a limited subset of chromosomal regions was
examined, the results suggest that these oncosuppressor
genes, commonly implicated in other human tumours, do not
play a significant role in cervical carcinogenesis.
Allele deletions on chromosome 17p have been reported in
up to 61% of breast carcinomas (Mackay et al., 1988a);
73.1% of osteosarcomas (Toguchida et al., 1989); 75% of
colonic carcinomas (Vogelstein et al., 1988); 50-60% of
epithelial ovarian carcinomas (Eccles et al., 1990; Russell et
al., 1990); up to 55% of brain tumours (Fults et al., 1989)
and 63% of bladder carcinomas (Tsai et al., 1990) - sugges-
ting the presence of a tumour suppressor gene that is
involved in a carcinogenetic mechanism common to all of
these tumours. Our data show only 15% of informative
tumours with 17p allele loss; a similar proportion to that
identified in a recently published series of cervical carcinomas
(Kaelbling et al., 1992), but a significantly lower proportion
(P<0.05; Fisher's Exact Test) than that observed using
similar probes in tumours of breast, bladder, ovary, bone,
and colon. This may imply that any association between 17p
allele loss and carcinogenesis does not extend to cervical
carcinoma.
An association between the HPV E6 and E7 genes and the
p53 (17p) and Rb (13q) genes respectively, has been sug-
gested (Banks et al., 1990; Crook et al., 1991; Scheffner et al.,
1991). Inactivated p53 protein has been associated with HPV
16 E6 oncoprotein complex formation (Scheffner et al., 1991) while the Rb gene cellular protein has been associated with
HPV 16 E7 protein (Banks et al., 1990; Scheffner et al.,
1991). In studies on cervical carcinoma cell lines, and more
recently on cervical tumour tissue, wild type p53 mRNA and
DNA were sequenced from HPV positive cell lines and
tumours respectively, while the mutated form was detected
only in those that were HPV negative; suggesting that alter-
native and mutually exclusive routes for altering p53 function
are adopted in cervical carcinogenesis: mutation, or complex formation with HPV E6 (Crook et al., 1991; 1992). The
results of our study are not wholly consistent with this
proposition, in that two of three cases showing LOH at 17p, in the vicinity of the p53 gene, were HPV positive. However, it is possible that p53 may yet exert a dominant negative effect, with its function altered by mutation in the absence of
LOH on chromosome 17p.
Research on cervical carcinoma cell lines has suggested a
role for genes on chromosome 11. Microcell transfer of a
single copy of fibroblast chromosome 11 into tumorigenic HeLa cells converted them into a non-tumorigenic state
(Saxon et al., 1986); and a putative tumour suppressor gene identified in HeLa cells has been mapped to the chromosome
llq.13 region (Srivatsan et al., 1991). Loss of heterozygosity
on chromosome 11, in 30% of cervical carcinoma cases, has
been reported in a recent study (Srivatsan et al., 1991); while
36% LOH on chromosome lp had been reported in a
previous series (Riou et al., 1988). Our analysis using four
markers on the short arm of chromosome 11 revealed a
frequency of LOH lower than that observed with equivalent probes in breast cancer; and, for three of the four probes used, the incidence of LOH was distinctly lower than that
observed at the 'innocent' locus on 8q. It therefore appears
unlikely that an oncosuppressor gene ofmajor importance to
cervical carcinogenesis resides on the short arm of chromo-
some 11. An analysis of the long arm of this chromosome
Table III Comparative loss of heterozygosity: Published series of other tumour types vs this
series of cervical carcinomas
This series -
Published series- other tumours cervical carcinoma
CHR Tumour type (Ref.) A/B % A/Ba % p
17p Breast (Devilee et al., 1989) 30/49 61 1/12 8 0.001
Bladder (Tsai et al., 1990) 15/24 63 1/12 8 0.004
Ovary (Eccles et al., 1992) 10/18 56 1/9 11 0.042
Bone (Toguchida et al., 1989) 19/26 73 3/20 15 <0.001
Colon (Vogelstein et al., 1988) 45/60 75 3/20 15 <0.001
17q Ovary (Eccles et al., 1990) 10/13 77 0/13 0 <0.001
13q Breast (Devilee et al., 1989) 12/32 38 0/14 0 <0.001
Bone (Toguchida et al., 1988) 13/30 43 0/14 0 <0.001
lip Breast (Mackay et al., 1988b) 4/7 57 1/14 7 0.025
Bladder (Tsai et al., 1990) 9/23 39 1/15 7 NS
Sq Colon (Ashton-Rickardt et al., 1991) 44/106 42 5/16 31 NS
3p Lung (Naylor et al., 1987) 9/9 100 1/4 25 0.014
Kidney (Zbar et al., 1987) 11/11 100 1/4 25 0.009
18q Colon (Fearon et al., 1990) 29/41 71 1/5 20 0.018
CHR = Chromosome. A = No. ofcases with loss ofheterozygosity. B = No. ofinformative
cases. % = Percentage ofinformativecaseswith lossofheterozygosity. aSameprobe/susedin this
series as in published series compared. P = P-value (Fisher's Exact Test). NS = Not statistically
significant.
Table II Allele losses74 R.M.C. BUSBY-EARLE et al.
was not performed because of the unavailability of DNA
probes.
Similarly, losses on chromosome 5q in the region of the
APC and MCC tumour suppressor genes, and on 18q in the
vicinity of the DCC gene have been associated with colorec-
tal cancer at levels of 41.5% (Ashton-Rickardt et al., 1991),
and 71.0% (Fearon et al., 1990) respectively, but, a high level
of LOH was not detected at these loci in cervical carcinoma.
Previously published work in this field reported the occur-
rence of allele losses in nine of nine informative cases on
chromosome 3 at p14-21 (Yokota et al., 1989). Although our
results do not directly refute this finding, as the probe used
by Yokota et al., was not available to us, we demonstrated
no significant LOH at a locus just bordering this region
(3p.21).
Human papilloma viruses, especially types 16 and 18, have
long been associated with malignancy in the cervix (Bosch et
al., 1989; zur Hausen, 1989; Chang, 1990; Singer & Jenkins,
1991). This association has been confirmed by PCR in 75%
of the cases in the present study. However, our finding that
common HPV types 6, 11, 16, 18 and 33 were absent in 25%
of the tumours examined suggests that HPV infection may
not be a prerequisite for malignant transformation in the
cervix. Both HPV-positive and HPV-negative tumours
showed a low frequency of LOH, and there was no consistent
relationship between LOH and the integrated or episomal
state of the virus. This suggests that cervical carcinoma cells
arrive at the malignant phenotype by pathways which are
probably different from those identified in other common
solid tumours, but which do not necessarily involve the
common HPV types.
If oncosuppressor genes are involved in cervical car-
cinogenesis, they are probably found at loci different from
those commonly deleted in other solid tumours. Alterna-
tively, a different mode of carcinogenesis, perhaps involving
HPV or other virus types, may be involved.
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